SCHEMBL19119062

SCHEMBL19119062

CC(C)(C(=O)O)c1ccc(Nc2nc(C(F)(F)F)cs2)cc1.[NaH]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR4 P51679 2/20 0.50
▸ CFTR P13569 1/20 0.44
▸ GAA P10253 2/20 0.44
▸ KDM4E B2RXH2 4/20 0.43
▸ MAPT P10636 4/20 0.43
▸ POLB P06746 2/20 0.43
▸ ALOX5 P09917 2/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.42
▸ NPY5R Q15761 1/20 0.42
▸ MAPK1 P28482 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KDM1A O60341 3/20 0.41
▸ FFAR2 O15552 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263507 0.99 CCR4 (0.51) CCR4CFTRGAAKDM4EMAPT
SCHEMBL5439494 0.89 CCR4 (0.51) CCR4CFTRGAAKDM4EMAPT
SCHEMBL19119063 0.86 CCR4 (0.46) CCR4CFTRGAAKDM4EMAPT
SCHEMBL29274266 0.81 ALOX5 (0.59) CCR4CFTRGAAKDM4EMAPT
SCHEMBL1821848 0.79 ALOX5 (0.60) CCR4CFTRGAAKDM4EMAPT
SCHEMBL2185593 0.79 FFAR2 (0.50) CCR4CFTRGAAMAPTNPC1
SCHEMBL27818106 0.79 FFAR2 (0.50) CCR4CFTRGAAMAPTNPC1
Propionic Acid SCHEMBL27837747 0.79 GAA (0.47) CCR4CFTRGAAKDM4EMAPT
SCHEMBL14625491 0.79 CCR4 (0.51) CCR4CFTRGAAKDM4EMAPT
SCHEMBL5437969 0.78 KDM1A (0.59) CCR4CFTRGAAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3192504-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY Dompé farmaceutici S.p.A. (IT) 2017-07-19 — — EP claimed
EP-3402474-B1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY DOMPE FARM SPA (IT) 2021-07-21 — — EP disclosed
US-20190015391-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY DOMPÉ FARMACEUTICI S.P.A. (IT) 2019-01-17 — — US disclosed
EP-3402474-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY Dompé farmaceutici S.p.A. (IT) 2018-11-21 — — EP disclosed
WO-2017121838-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY DOMPE' FARMACEUTICI S.P.A. (IT) 2017-07-20 — — WO disclosed
EP-3192504-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY Dompé farmaceutici S.p.A. (IT) 2017-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190015391-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY CXCL8, CCR8, CXCR1 CCR4 31/4885CFTR 2371/4885GAA 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback